Every month, CREATION.co’s tracking updates bring you the latest insights from the conversation of healthcare professionals (HCPs) across the globe discussing product launches. Discover which new drug approvals HCPs are talking about, what they think about them, and which online sources they are using to inform their opinions and conversations in CREATION.co’s latest tracking update.
Throughout December 2022 we tracked the global conversations of 1,624 HCPs who posted 2,213 English-language Twitter posts about the launches and approvals of new products.
Over the course of December, HCPs discussed several newly approved products including a gene therapy treatment for bladder cancer, a capsid inhibitor for multi-drug resistant HIV, and a faecal microbiota treatment for prevention of recurrence of clostridioides difficile infection. This year, much of the HCP conversation quietened over the Christmas and new year period, with most of the discussion occurring at the start of the month.
At the start of the month, HCPs were particularly interested in the FDA approval of the first faecal microbiota product, Rebyota, manufactured by Ferring Pharmaceuticals, which is used for the prevention of recurrence of Clostridioides difficile infection (CDI) in adult patients. HCPs considered this a significant breakthrough, beyond just the infectious disease space, suggesting that the technology may also lead to advancements in the treatment of cancer and inflammatory conditions.
FDA Approves First Fecal Microbiota Product | this is a breakthrough advance beyond the infectious disease field, because microbiota modulation is going to be a key pillar for the treatment of cancer and different inflammatory conditions @MaaT_Pharma https://t.co/B20JJfm0G8
— Mohamad Mohty (@Mohty_EBMT) December 1, 2022
Another story which generated discussion among HCPs was the FDA approval of the first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer. The product, Adstiladrin (nadofaragene firadenovec-vncg), which is also manufactured by Ferring Pharmaceuticals, was celebrated as good news for patients, with HCPs also highlighting the decades of research which led to this approval.
Good New for Patients !!! The FDA has approved nadofaragene firadenovec-vncg (Adstiladrin) as the first gene therapy for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)–unresponsive NMIBC with CIS with or w/o papillary tumors. @BladderCancerUS
— joaquim bellmunt (@OncoBellmunt) December 16, 2022
— Deb Sundi (@DebSundi) December 17, 2022
HCPs also expressed interest in a new precision medicine treatment for non-small cell lung cancer (NSCLC). Krazati (adagrasib), of Mirati Therapeutics, received FDA approval on December 12th for pre-treated KRAS-G12C lung cancer patients, offering a second option alongside another product, sotorasib. One HCP declared the approval as a ‘win for a subset of patients for whom progress is long overdue’.
🚨 It's just Monday & we have another #precisionmedicine FDA approved !!! 🎯🧬🫁 #LCSM
📢 ADAGRASIB is now FDA approved for KRAS G12C #lungcancer
Brand name is "Krazati"
KRAS G12C patients have 2 options- Sotorasib & now this. https://t.co/WoZfyGGJGY
— Vivek Subbiah, MD (@VivekSubbiah) December 12, 2022
A second KRAS G12C inhibitor receives FDA accelerated approval for pre-treated KRAS G12C-mt NSCLC
— Jarushka Naidoo (@DrJNaidoo) December 12, 2022
Lastly, HCPs also commented on the approval of Gilead’s Sunlenca (lenacapavir) for patients with multi-drug resistant HIV. HCPs shared the news of the approval but were tentative to offer their opinions on the treatment, with one HCP sharing that they were waiting to hear more about the pricing of the treatment before offering further comment.
#Lenacapavir, the first capsid inhibitor, has been approved for people with multi-drug resistant HIV in the US. Injections are every 6 mo. Waiting for pricing info… 💰@HIVMA @IAS_USA @GileadSciences press release 👇
— Melanie Thompson (@drmt) December 22, 2022
The three most shared links from HCPs discussing product launches in December were:
- An FDA press release on the approval of the first faecal microbiota product, Rebyota.
- A PR Newswire article announcing the FDA approval of the first gene therapy for the treatment pof high-risk, non-muscle-invasive bladder cancer.
- A Gilead press release on Sunlenca (lenacapavir) receiving FDA approval as a first-in-class, twice-yearly treatment option for people living with multi-drug resistant HIV.
Each month, CREATION.co tracks the HCP conversation relating to new product launches.
You can keep up to date with this and a variety of other topics including virtual congress, healthcare changes since the pandemic, product development and therapy area specific insights within the Tracking section of CREATION Knowledge, or sign up to receive our monthly eJournal with all of our latest HCP insights.
To stay up to date, you can sign up to CREATION.co’s monthly eJournal.
- Using CREATION Pinpoint® the English-language Twitter conversations of HCPs globally discussing new pharmaceutical product launches and drug approvals between 1 November and 30 November 2022 were analysed in order to discover which new product launches HCPs are discussing as well as #WhatHCPsThink.
- Mentions of drug approvals by the FDA, EMA, NICE, and CHMP were included in the data, as well as mentions of ‘drug approval’ by HCPs in their Twitter conversations.
- Between 1 November and 30 November 2022, there were 2,465 HCP mentions of new pharmaceutical product launches and drug approvals from 1,811 unique HCP authors from around the world.
Click here to view the latest Product Launch Tracker